Abstract
The elevated level of dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) is associated with the pathology of neurodegenerative diseases and has been implicated in some neurobiological alterations of Down syndrome, such as mental retardation. In the present article, a pharmacophore based 3D-QSAR model was developed for a series of leucettines possessing Dyrk1A inhibitory activity. The crucial molecular features observed in the developed pharmacophore model that account for binding affinity of ligands with the enzyme, include three H-bond acceptors (A), one positive ionic site (P) and one hydrophobic aromatic ring (R). Excellent statistical results of QSAR model such as good correlation coefficient (r > 0.9), higher F value (F > 20), excellent predictive power (Q2 > 0.6) and higher enrichment of known actives during virtual screening application strongly suggest that the developed model will be highly useful in designing new inhibitors and for predicting activity of new inhibitors.
Keywords: Anti-Alzheimers, Dyrk1A, Leucettines, Pharmacophore model, 3D-QSAR, Partial least square analysis.
Letters in Drug Design & Discovery
Title:Pharmacophore Based 3D-QSAR Modeling and Molecular Docking of Leucettines as Potent Dyrk1A Inhibitors
Volume: 10 Issue: 8
Author(s): Anu Bahl, Prashant Joshi, Sandip B. Bharate and Harish Chopra
Affiliation:
Keywords: Anti-Alzheimers, Dyrk1A, Leucettines, Pharmacophore model, 3D-QSAR, Partial least square analysis.
Abstract: The elevated level of dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) is associated with the pathology of neurodegenerative diseases and has been implicated in some neurobiological alterations of Down syndrome, such as mental retardation. In the present article, a pharmacophore based 3D-QSAR model was developed for a series of leucettines possessing Dyrk1A inhibitory activity. The crucial molecular features observed in the developed pharmacophore model that account for binding affinity of ligands with the enzyme, include three H-bond acceptors (A), one positive ionic site (P) and one hydrophobic aromatic ring (R). Excellent statistical results of QSAR model such as good correlation coefficient (r > 0.9), higher F value (F > 20), excellent predictive power (Q2 > 0.6) and higher enrichment of known actives during virtual screening application strongly suggest that the developed model will be highly useful in designing new inhibitors and for predicting activity of new inhibitors.
Export Options
About this article
Cite this article as:
Bahl Anu, Joshi Prashant, Bharate B. Sandip and Chopra Harish, Pharmacophore Based 3D-QSAR Modeling and Molecular Docking of Leucettines as Potent Dyrk1A Inhibitors, Letters in Drug Design & Discovery 2013; 10(8) . https://dx.doi.org/10.2174/15701808113100890024
DOI https://dx.doi.org/10.2174/15701808113100890024 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience
Current Pharmaceutical Design The Protective Effects of Extra Virgin Olive Oil on Immune-mediated Inflammatory Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Dev elopment (Part C))
Current Pharmaceutical Design Childhood Alopecia Areata: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Alzheimers Disease: Pathological Mechanisms and Recent Insights
Current Neuropharmacology Inflammatory and Cell Death Pathways in Brain and Peripheral Blood in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Molecule of the Month
Current Topics in Medicinal Chemistry Omega – 3 Fatty Acids as Pharmacotherapeutics in Psoriasis: Current Status and Scope of Nanomedicine in its Effective Delivery
Current Drug Targets Antipsychotic and Antiepileptic Drugs in Bipolar Disorder: The Importance of Therapeutic Drug Monitoring
Current Medicinal Chemistry The Many Roles of Statins in Ischemic Stroke
Current Neuropharmacology Hypertension, Diabetes and Neurodegenerative Diseases: Is there a Clinical Link through the Ca2+/cAMP Signalling Interaction?
Current Hypertension Reviews Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Purine-Scaffold Hsp90 Inhibitors
Current Topics in Medicinal Chemistry Discovery of Neurogenic, Alzheimers Disease Therapeutics
Current Alzheimer Research Pharmacological Potential of Exercise and RAS Vasoactive Peptides for Prevention of Diseases
Current Protein & Peptide Science Targeting Insulin Signaling for the Treatment of Alzheimer's Disease
Current Topics in Medicinal Chemistry Triptan-Induced Torsades de Pointes and Ventricular Fibrillation Cardiac Arrest: Case Report and Review of the Literature
Current Drug Safety Microwave Assisted Organic Synthesis (MAOS) of New Dispacamide A Derivatives Bearing a Thiazolinone Platform, Biological Assays on Inhibition of Protein Kinases and Cell Effects
Current Microwave Chemistry Investigation of 5-HT<sub>2A</sub> gene expression in PBMCs of patients with allergic asthma
Inflammation & Allergy - Drug Targets (Discontinued) Clinical Characteristics and Treatment of Cardiomyopathies in Children
Current Cardiology Reviews